Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3065 |
|
| Actual shortage: | 232 (8%) | |
| Anticipated shortage: | 15 (0%) | |
| Avoided shortage: | 9 (0%) | |
| Resolved: | 2809 (92%) | |
Discontinuation Reports |
356 |
|
| To be discontinued: | 22 (6%) | |
| Discontinued: | 334 (94%) | |
| Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
31 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-02-05 | 2021-03-30 | 133385 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-02-19 | 2021-03-17 | 134439 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-06-04 | 2021-06-22 | 140420 |
| APO-NAPROXEN EC | 375MG | TABLET (ENTERIC-COATED) | Resolved | 2021-06-04 | 2021-06-14 | 140423 |
| APO-NAPROXEN EC | 375MG | TABLET (ENTERIC-COATED) | Resolved | 2021-09-24 | 2021-10-05 | 146157 |
| APO-NAPROXEN EC | 375MG | TABLET (ENTERIC-COATED) | Resolved | 2022-01-14 | 2022-02-07 | 152770 |
| APO-NAPROXEN EC | 375MG | TABLET (ENTERIC-COATED) | Resolved | 2022-08-11 | 2022-10-20 | 166445 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2022-09-01 | 2022-11-20 | 168421 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2023-09-07 | 2023-10-13 | 203849 |
| ZAMINE 28 | 3MG 0.03MG | TABLET | Resolved | 2021-02-12 | 2021-03-10 | 133984 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Resolved | 2019-01-30 | 2020-04-04 | 74019 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2019-06-12 | 2019-10-07 | 86336 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2021-07-05 | 2021-12-03 | 141854 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-06-12 | 2022-07-28 | 162475 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2023-09-28 | 2024-01-05 | 205501 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-22 | 2024-01-12 | 214220 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2024-05-03 | 2024-05-17 | 227085 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 4.0G 0.5G | POWDER FOR SOLUTION | Actual shortage | 2017-03-11 | 2017-10-05 | 580 |
| APO-RISPERIDONE | 4.0MG | TABLET | Resolved | 2019-10-09 | 2019-10-29 | 95882 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2017-03-11 | 2017-05-18 | 487 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LISINOPRIL/HCTZ | 12.5MG 10MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1093 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-VALSARTAN/HCTZ | 12.5MG 160MG | TABLET | Discontinued | 2019-01-03 | 2019-01-03 | 71054 |
| APO-LISINOPRIL/HCTZ | 12.5MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1090 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60603 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Discontinued | 2019-01-03 | 2019-01-03 | 71101 |
| APO-TELMISARTAN/HCTZ | 12.5MG 80MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40823 |
| APO-TELMISARTAN/HCTZ | 12.5MG 80MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40826 |
| APO-TELMISARTAN/HCTZ | 12.5MG 80MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 40957 |
| APO-CARVEDILOL | 12.5MG | TABLET | To be discontinued | 2024-01-26 | 2024-04-01 | 217493 |
| APO-DILTIAZ TZ | 120MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2017-03-13 | 2017-03-13 | 1064 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-AMOXI CLAV 125MG/31.25MG PER 5ML | 125MG 31.25MG | POWDER FOR SUSPENSION | Discontinued | 2017-03-31 | 2017-03-31 | 4903 |
| APO-AMOXI SUGAR FREE | 125MG | POWDER FOR SUSPENSION | Discontinued | 2018-09-07 | 2018-09-15 | 60246 |